Clinical trial
Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid…
NCT00424346 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00424346 |
|---|---|
| Title | Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis |
| Official title | A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) With Three Different Dose Regimens in Patients With Active Rheumatoid Arthritis Despite… |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Canakinumab, Placebo |
| Enrollment | 274 |
| Start date | Nov 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Oct 1, 2009 |
| First posted | Jan 19, 2007 |
| Last update posted | Feb 10, 2014 |
| Countries | Austria, Belgium, Canada, Germany, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: